Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation)

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Cystic Fibrosis
Interventions
DRUG

GLPG1837 dose 1

two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for one week

DRUG

GLPG1837 dose 2

two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for one week

DRUG

GLPG1837 dose 3

two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for two weeks

Trial Locations (16)

Unknown

Royal Adelaide Hospital, Adelaide

The Prince Charles Hospital, Chermside

Monash Medical Centre, Clayton

Sir Charles Gairdner Hospital, Nedlands

Mater Adult Hospital, South Brisbane

Fakultni nemocnice v Motole, Prague

Charité Universitätsmedizin Berlin, Berlin

Universitätsklinkikum Koeln, Cologne

Uniklinik Carl-Gustav-Carus, Dresden

Lungenheilkunde München-Pasing, München

Beamont Hospital, Dublin

St. Vincent's University Hospital, Dublin

Queen Elizabeth University Hospital, Glasgow

Liverpool Heart and Chest Hospital, Liverpool

Royal Brompton Hospital, London

The Medicines Evaluation Unit Ltd, Manchester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Galapagos NV

INDUSTRY